Replimune Group Files 8-K
Ticker: REPL · Form: 8-K · Filed: 2025-01-22T00:00:00.000Z
Sentiment: neutral
Topics: corporate-disclosure, financials
TL;DR
Replimune filed an 8-K on Jan 21, 2025, reporting other events and financials.
AI Summary
Replimune Group, Inc. filed an 8-K on January 22, 2025, reporting other events and financial statements/exhibits. The filing date indicates the earliest event reported was January 21, 2025. The company is incorporated in Delaware and headquartered in Woburn, MA.
Why It Matters
This 8-K filing provides updates on Replimune Group's corporate activities and financial reporting, which are important for investors to monitor the company's status.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new risks.
Key Players & Entities
- Replimune Group, Inc. (company) — Registrant
- January 21, 2025 (date) — Earliest event reported
- January 22, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Woburn, MA (location) — Principal executive offices
- 001-38596 (identifier) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of January 21, 2025.
When was the earliest event reported in this filing?
The earliest event reported was on January 21, 2025.
What is Replimune Group, Inc.'s principal executive office address?
The principal executive offices are located at 500 Unicorn Park Drive, Suite 303, Woburn, MA 01801.
In which state is Replimune Group, Inc. incorporated?
Replimune Group, Inc. is incorporated in Delaware.
What is the SEC file number for Replimune Group, Inc.?
The SEC file number for Replimune Group, Inc. is 001-38596.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 11.2 · Accepted 2025-01-22 17:00:22
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Mar
Filing Documents
- tm254066d1_8k.htm (8-K) — 25KB
- tm254066d1_ex99-1.htm (EX-99.1) — 12KB
- tm254066d1_ex99-1img001.jpg (GRAPHIC) — 5KB
- 0001104659-25-005291.txt ( ) — 217KB
- repl-20250121.xsd (EX-101.SCH) — 3KB
- repl-20250121_lab.xml (EX-101.LAB) — 33KB
- repl-20250121_pre.xml (EX-101.PRE) — 22KB
- tm254066d1_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On January 21, 2025, Replimune Group, Inc. (the "Company") issued a new release announcing that the U.S. Food and Drug Administration (FDA) accepted the Company's Biologics License Application for RP1 in combination with nivolumab for patients with advanced melanoma. A copy of the news release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein. The Company undertakes no obligation to update, supplement or amend the materials attached hereto.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. Exhibit No. Description 99.1 News Release dated January 21, 2025 104 Cover page interactive data file (formatted as Inline XBRL)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. REPLIMUNE GROUP, INC. Date: January 22, 2025 By: /s/ Sushil Patel Sushil Patel Chief Executive Officer